Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 5/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3203100 | 1.00 | ACHE (0.48) | ACHEHTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL15188938 | 1.00 | ACHE (0.48) | ACHEHTR2AHTR2CHTR2BKDM1A | |
| Hydrochloric Acid SCHEMBL3175686 | 0.98 | ACHE (0.47) | ACHEHTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL4014236 | 0.89 | HTR2A (0.46) | ACHEHTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL484695 | 0.89 | HTR2A (0.46) | ACHEHTR2AHTR2CHTR2BKDM1A | |
| Hydrochloric Acid SCHEMBL16535589 | 0.87 | ACHE (0.47) | ACHEHTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL27080967 | 0.85 | KDM1A (0.45) | ACHEHTR2AHTR2CKDM1ANOS3 | |
| Methylamine SCHEMBL27747617 | 0.85 | HTR2A (0.47) | ACHEHTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL14575715 | 0.85 | KDM1A (0.45) | ACHEHTR2AHTR2CKDM1ANOS3 | |
| SCHEMBL27080511 | 0.85 | KDM1A (0.45) | ACHEHTR2AHTR2CKDM1ANOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | JOHN VARGHESE | 2010-06-10 | — | — | US | disclosed |
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | JOHN VARGHESE | 2010-06-10 | — | — | US | disclosed |
| US-7645780-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645780-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7544717-B2 | 2-amino- and 2-thio- substituted 1,3-diaminopropanes | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544717-B2 | 2-amino- and 2-thio- substituted 1,3-diaminopropanes | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20080249139-A1 | Benzamide 2-hydroxy-3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7244725-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244725-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244725-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1751091-A2 | 2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES | Elan Pharmaceuticals, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20050267199-A1 | 2-Amino- and 2-thio- substituted 1,3-diaminopropanes | ELAN PHARMACEUTICALS, INC. | 2005-12-01 | — | — | US | disclosed |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| WO-2005095326-A2 | 2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES | ELAN PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20040180939-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | BACE1, BACE2, APP | ACHE 38/4885HTR2A 1890/4885HTR2C 2407/4885 |
| US-20080249139-A1 | Benzamide 2-hydroxy-3-diaminoalkanes | BACE2, BACE1, APP | ACHE 45/4885HTR2A 883/4885HTR2C 1290/4885 |
| US-20040180939-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | BACE1, BACE2, APP | ACHE 72/4885HTR2A 1485/4885HTR2C 1888/4885 |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | APP, DNPEP, BACE1 | ACHE 965/4885HTR2A 4140/4885HTR2C 4738/4885 |
| US-20050267199-A1 | 2-Amino- and 2-thio- substituted 1,3-diaminopropanes | BACE1, APP, BACE2 | ACHE 49/4885HTR2A 1954/4885HTR2C 2819/4885 |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | BACE1, BACE2, APP | ACHE 38/4885HTR2A 1890/4885HTR2C 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.